Most recently, Amgen faced the kind of legal challenges normally reserved for big pharma, with allegations of allegedly violating anti-kickback rules by “overfilling” Aranesp vials.

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.